rbd7022
Nucleic acidexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 17, 2023 (NCT05912296)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Subtilisin/kexin type 9ANTISENSE INHIBITOR
PCSK9 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07074236 | Phase 1 | Jul 31, 2025 | Qilu Pharmaceutical Co., Ltd. |
| NCT05912296 | Phase 1 | May 17, 2023 | Chinese Academy of Medical Sciences, Suzhou Ribo Life Science Co. Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Qilu Pharmaceutical Co., Ltd. | For profit | 1 | 1 | 1 | 2025 |
| Suzhou Ribo Life Science Co. Ltd. | For profit | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1